KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBIT Margin (2018 - 2025)

Historic EBIT Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 3.09%.

  • BioNTech SE's EBIT Margin fell 39300.0% to 3.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.0%, marking a year-over-year increase of 17100.0%. This contributed to the annual value of 47.77% for FY2024, which is 658500.0% down from last year.
  • According to the latest figures from Q3 2025, BioNTech SE's EBIT Margin is 3.09%, which was down 39300.0% from 192.14% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBIT Margin registered a high of 81.15% during Q1 2021, and its lowest value of 750.74% during Q2 2024.
  • Moreover, its 5-year median value for EBIT Margin was 12.49% (2024), whereas its average is 63.61%.
  • In the last 5 years, BioNTech SE's EBIT Margin plummeted by -4148400bps in 2024 and then soared by 5586000bps in 2025.
  • Over the past 5 years, BioNTech SE's EBIT Margin (Quarter) stood at 0.0% in 2021, then surged by 90606241bps to 76.97% in 2022, then crashed by -54bps to 35.58% in 2023, then plummeted by -65bps to 12.49% in 2024, then tumbled by -125bps to 3.09% in 2025.
  • Its last three reported values are 3.09% in Q3 2025, 192.14% for Q2 2025, and 292.18% during Q1 2025.